Bicara Therapeutics BCAX
$8.44 −$0.68 (-7.46%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $8.44 0.00%
Open$8.83
Prev close$9.12
Day range$8.43 – $9.14
Volume814.5K
Market cap$560.31M
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$0.00
Operating profit-$75.71M-86.1% YoY
Net profit-$71.25M-96.1% YoY
Diluted EPS-$1.04-55.2% YoY
Free cash flow-$56.79M-93.9% YoY
Operating cash flow-$56.13M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Return on equity-54.2%
Return on assets-49.8%
Return on invested capital-56.6%
Current ratio8.81
Liabilities / assets11.1%
Cash & investments$442.35M
Total debt$0.00
Net cash (debt)$442.35M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Operating Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Expense | $75.71M | $59.95M | $60.24M | $155.60M | $41.12M |
| Selling and Admin Expenses | $19.24M | $14.18M | $12.74M | $30.51M | $8.13M |
| -General & Admin Expense | $19.24M | $14.18M | $12.74M | $30.51M | $8.13M |
| Research & Development | $56.48M | $45.77M | $47.50M | $125.10M | $32.99M |
| Operating Profit | -$75.71M | -$59.95M | -$60.24M | -$155.60M | -$41.12M |
| Net Non-Operating Interest Income (Expense) | $4.52M | $4.58M | $4.08M | $17.87M | $3.79M |
| Non-Operating Interest Income | $4.52M | $4.58M | $4.08M | $17.87M | $3.79M |
| Pretax Profit | -$71.20M | -$55.38M | -$56.16M | -$137.73M | -$37.33M |
| Tax | $54,000.00 | $61,000.00 | $52,000.00 | $217,000.00 | $53,000.00 |
| Net Profit | -$71.25M | -$55.44M | -$56.21M | -$137.95M | -$37.39M |
| Profit from Continuing Operations | -$71.25M | -$55.44M | -$56.21M | -$137.95M | -$37.39M |
| Net Income to Parent Company | -$71.25M | -$55.44M | -$56.21M | -$137.95M | -$37.39M |
| Net Income to Common Stockholders | -$71.25M | -$55.44M | -$56.21M | -$137.95M | -$37.39M |
| Basic EPS | -$1.04 | -$0.82 | -$0.93 | -$2.52 | -$0.68 |
| Diluted EPS | -$1.04 | -$0.82 | -$0.93 | -$2.52 | -$0.68 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $460.64M | $512.24M | $553.60M | $430.99M | $430.99M |
| Total Current Assets | $451.41M | $503.82M | $544.92M | $422.05M | $422.05M |
| Cash and Cash Equivalents & Short-Term Investments | $442.35M | $497.26M | $539.75M | $414.80M | $414.80M |
| -Cash and Cash Equivalents | $82.02M | $96.60M | $323.46M | $96.69M | $96.69M |
| -Short Term Investments | $360.33M | $400.66M | $216.29M | $318.12M | $318.12M |
| Other Current Assets | $9.06M | $6.56M | $5.16M | $7.25M | $7.25M |
| Total Non-Current Assets | $9.23M | $8.42M | $8.68M | $8.94M | $8.94M |
| Net PPE | $1.69M | $1.51M | $1.77M | $2.03M | $2.03M |
| -Gross PPE | $1.69M | $1.51M | $1.77M | $2.03M | $2.03M |
| Other Non-Current Assets | $7.54M | $6.91M | $6.91M | $6.91M | $6.91M |
| Total Liabilities | $51.23M | $43.48M | $39.64M | $29.54M | $29.54M |
| Total Current Liabilities | $51.23M | $43.48M | $39.34M | $28.95M | $28.95M |
| Payables | $3.64M | $8.46M | $7.44M | $7.79M | $7.79M |
| -Accounts Payable | $3.64M | $8.46M | $7.44M | $7.79M | $7.79M |
| Current Accrued Expenses | $40.00M | $29.80M | $28.85M | $15.00M | $15.00M |
| Short-Term Debt and Capital Lease Obligation | $880,000.00 | $1.16M | $1.14M | $1.12M | $1.12M |
| -Current Capital Lease Obligation | $880,000.00 | $1.16M | $1.14M | $1.12M | $1.12M |
| Total Non-Current Liabilities | $0.00 | $0.00 | $301,000.00 | $593,000.00 | $593,000.00 |
| Long Term Debt and Capital Lease Obligation | $0.00 | $0.00 | $301,000.00 | $593,000.00 | $593,000.00 |
| -Long Term Capital Lease Obligation | $0.00 | $0.00 | $301,000.00 | $593,000.00 | $593,000.00 |
| Total Equity | $409.41M | $468.77M | $513.96M | $401.45M | $401.45M |
| Stockholders' Equity | $409.41M | $468.77M | $513.96M | $401.45M | $401.45M |
| Capital Stock | $8,000.00 | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Common Stock | $8,000.00 | $8,000.00 | $8,000.00 | $7,000.00 | $7,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $953.13M | $939.94M | $929.37M | $760.17M | $760.17M |
| Retained Earnings | -$541.86M | -$470.61M | -$415.18M | -$358.97M | -$358.97M |
| Gains/Losses Not Affecting Retained Earnings | -$1.87M | -$567,000.00 | -$243,000.00 | $243,000.00 | $243,000.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$56.13M | -$44.21M | -$37.51M | -$106.83M | -$23.89M |
| Net cash flow from continuing operations | -$56.13M | -$44.21M | -$37.51M | -$106.83M | -$23.89M |
| Net Income from Continuing Operations | -$71.25M | -$55.44M | -$56.21M | -$137.95M | -$37.39M |
| Depreciation & Depletion & Amortization | $60,000.00 | $44,000.00 | $44,000.00 | $105,000.00 | $43,000.00 |
| Other Non-Cash Items | $428,000.00 | $277,000.00 | $273,000.00 | $895,000.00 | $297,000.00 |
| Change in Working Capital | $4.62M | $2.43M | $12.19M | $14.81M | $8.44M |
| -Change in Prepaid Assets | -$3.14M | -$1.40M | $2.09M | $5.28M | $839,000.00 |
| -Change in Payables and Accrued Expense | $8.04M | $4.11M | $10.37M | $10.46M | $7.90M |
| -Change in Other Current Liabilities | -$283,000.00 | -$277,000.00 | -$270,000.00 | -$932,000.00 | -$292,000.00 |
| Net cash flow from investing | $38.34M | -$184.99M | $100.94M | -$318.45M | -$82.33M |
| Net Cash Flow from Continuing Investing Activities | $38.34M | -$184.99M | $100.94M | -$318.45M | -$82.33M |
| Net PPE Purchase and Sale | -$663,000.00 | -$60,000.00 | -$60,000.00 | -$280,000.00 | -$238,000.00 |
| Net Investment Purchase and Sale | $39.00M | -$184.93M | $101.00M | -$318.17M | -$82.09M |
| Financing Cash Flow | $3.21M | $2.33M | $163.35M | $32.26M | $31.23M |
| Net Cash Flow from Continuing Financing Activities | $3.21M | $2.33M | $163.35M | $32.26M | $31.23M |
| Net Common Stock Issuance | $0.00 | $0.00 | $161.76M | $29.50M | $29.50M |
| Proceeds from Stock Option Exercised | $3.21M | $2.33M | $1.58M | $2.76M | $1.73M |
| Ending Cash Balance | $82.02M | $96.60M | $323.46M | $96.69M | $96.69M |
| Net Change in Cash | -$14.58M | -$226.86M | $226.78M | -$393.03M | -$74.99M |
| Beginning Cash Balance | $96.60M | $323.46M | $96.69M | $489.71M | $171.67M |
| Free Cash Flow | -$56.79M | -$44.27M | -$37.57M | -$107.11M | -$24.12M |
No comments yet — be the first to weigh in on BCAX.
Sign in to join the discussion.